Stay updated on Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial

Sign up to get notified when there's something new on the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:48:12.000Z thumbnail image
  6. Check
    12 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the cumulative response rate obtained by a combination strategy involving pembrolizumab and an EGFR inhibiting agent in the treatment of locally advanced or metastatic squamous cell cancer of the skin.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:37.000Z thumbnail image
  7. Check
    27 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    16%
    Check dated 2024-05-22T21:26:23.000Z thumbnail image
  8. Check
    49 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:55:05.000Z thumbnail image

Stay in the know with updates to Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunotherapy +/- EGFR Inhibitor in Advanced cSCC Clinical Trial page.